Director at Wellgistics (WGRX) awarded 5M shares and 5M low‑price warrants

Rhea-AI Filing Summary

Wellgistics Health, Inc. director Surendra K. Ajjarapu received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, bringing his direct holdings to 7,882,247 shares.

He was also granted 5,000,000 warrants to purchase common stock at an exercise price of $0.01 per share, expiring on March 31, 2031. The footnotes state both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider AJJARAPU SURENDRA K

Role null

Type	Security	Shares	Price	Value
Grant/Award	Warrant	5,000,000	$0.01	$50K
Grant/Award	Common Stock	5,000,000	$0.20	$1.00M

Holdings After Transaction: Warrant — 5,000,000 shares (Direct, null); Common Stock — 7,882,247 shares (Direct, null)

Footnotes (1)

1. The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

Key Figures

Common stock granted: 5,000,000 shares Reported value per share: $0.20 per share Director holdings after grant: 7,882,247 shares +3 more

6 metrics

Common stock granted 5,000,000 shares Non-derivative award on March 31, 2026

Reported value per share $0.20 per share Common stock grant on March 31, 2026

Director holdings after grant 7,882,247 shares Common stock directly owned after March 31, 2026 transaction

Warrants granted 5,000,000 warrants Derivative award on March 31, 2026

Warrant exercise price $0.01 per share Exercise price for 5,000,000 warrants

Warrant expiration March 31, 2031 Expiration date of granted warrants

Key Terms

warrants, non-derivative, derivative, Section 4(a)(2) of the Securities Act of 1933, +1 more

5 terms

warrants financial

"The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

non-derivative financial

"transaction_type": "non-derivative""

derivative financial

"transaction_type": "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

Section 4(a)(2) of the Securities Act of 1933 regulatory

"exempt from registration under Section 4(a)(2) of the Securities Act of 1933"

exercise price financial

"conversion_or_exercise_price": "0.0100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AJJARAPU SURENDRA K

(Last) (First) (Middle)

C/O WELLGISTICS HEALTH, INC.

3000 BAYPORT DRIVE, SUITE 950

(Street)

TAMPA, FLORIDA 33607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wellgistics Health, Inc. [ WGRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		5,000,000(1)	A	$0.2	7,882,247	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	$0.01	03/31/2026		A		5,000,000(2)		03/31/2026	03/31/2031	Common Stock	5,000,000	$0.01	5,000,000	D

Explanation of Responses:

1. The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

2. The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

	/s/ Surendra K Ajjarapu	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Wellgistics Health (WGRX) director Surendra Ajjarapu receive in this Form 4?

Director Surendra K. Ajjarapu received a grant of 5,000,000 common shares and 5,000,000 warrants. These awards were issued as compensation for his service to Wellgistics Health, Inc., according to the Form 4 footnotes.

At what prices were the Wellgistics Health (WGRX) equity awards valued or exercisable?

The common stock grant was reported at $0.20 per share, while the warrants have an exercise price of $0.01 per share. These figures reflect the values used for reporting the compensation-related equity awards.

How many Wellgistics Health (WGRX) shares does Surendra Ajjarapu hold after this Form 4?

After the grant, Surendra K. Ajjarapu directly holds 7,882,247 shares of Wellgistics Health common stock. This total includes the newly awarded 5,000,000 shares disclosed in the Form 4 filing.

What are the key terms of the Wellgistics Health (WGRX) warrants granted to Surendra Ajjarapu?

Ajjarapu received 5,000,000 warrants to purchase Wellgistics Health common stock at $0.01 per share. The warrants were granted as compensation and are scheduled to expire on March 31, 2031, based on the Form 4 data.

Were the Wellgistics Health (WGRX) share and warrant grants registered with the SEC?

The footnotes state the 5,000,000 shares and 5,000,000 warrants were issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, meaning they were not registered public offerings.